Running a MLTX wheel strategy lets you generate consistent premium income on MoonLake Immunotherapeutics while setting your own entry and exit prices on the underlying. MoonLake Immunotherapeutics's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own MLTX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best MLTX wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on MLTX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable MLTX wheel from a losing one.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the MLTX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your MLTX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
